Mar, 2012

U.S.A.
News / Therapeutic Area News
Astellas Oncology Cycling Team Debuts with 12 Riders for 2012
Astellas Pharma US, Inc. (Astellas), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) today announced the debut of the Astellas...
Read More

Feb, 2012

U.S.A.
News / Therapeutic Area News
Medivation and Astellas Announce Positive Results from the Phase 3 AFFIRM Trial of MDV3100 in Prostate Cancer Patients Who Received Prior Chemotherapy
SAN FRANCISCO, CA and TOKYO -- January 31, 2012 -- Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (Tokyo: 4503) announced positive results on all efficacy endpoints from the Phase 3...
Read More

Jan, 2012

U.S.A.
News / Therapeutic Area News
Astellas and Theravance Announce Termination of License, Development and Commercialization Agreement for VIBATIV® (telavancin) for Injection
TOKYO, Japan and SOUTH SAN FRANCISCO, CA/January 6, 2012 — Astellas Pharma Inc. (Astellas) (Tokyo:4503) and Theravance, Inc. (NASDAQ: THRX) today announced that Astellas has exercised its right...
Read More
U.S.A.
News / Therapeutic Area News
AVEO and Astellas Announce Tivozanib Successfully Demonstrated Progression-Free Survival Superiority over Sorafenib in Patients with Advanced Renal Cell Cancer in Phase 3 TIVO-1 Trial
CAMBRIDGE, MASS. and TOKYO, JAPAN, January 3, 2012 – AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced that tivozanib demonstrated superiority over...
Read More

Dec, 2011

U.S.A.
News / Therapeutic Area News
Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL® DosePro® Effective March 31, 2012
SAN DIEGO, Calif. and Deerfield, Ill., December 21, 2011 — Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Read More